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Abstract U46619 is a potent platelet agonist, its binding to the
thromboxane A2 receptor resulting in Gq-binding protein-
mediated responses; nevertheless, it is unable to cause platelet
aggregation, unless released ADP is present. In this study we
demonstrate that Gi activation is the step U46619 lacks to cause
platelet aggregation; in fact, when platelets were treated with an
ADP scavenger system, the response to U46619 was restored by
the addition of epinephrine, which activates platelets via a Gi
protein. The concomitant activation of Gi and Gq proteins does
not require increased cytosolic calcium to cause aggregation, as
assessed by the fact that platelets treated with the intracellular
calcium chelator BAPTA were able to respond to U46619
provided ADP or epinephrine was present. Moreover, as the
calcium ionophore ionomycin, at low concentrations, potentiated
the response to U46619 but not to epinephrine, we may conclude
that calcium influx preferentially activates a Gi downstream
signalling pathway.
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1. Introduction
Platelet aggregation is crucial for primary hemostasis and
for the formation of platelet rich thrombi which could occlude
blood vessels in arterial diseases. During the last decade great
interest has been shown in focusing cell surface receptors in-
volved in platelet activation as well as in de¢ning the role of
heterotrimeric G proteins in mediating the interaction of such
receptors with downstream intracellular e¡ectors [1]. Recently,
the existence of two distinct G protein-coupled ADP receptors
on platelets, one (P2Y1) coupled to phospholipase C, involv-
ing Gq, and the other (P2TAC) to inhibition of adenylyl cy-
clase, via a Gi-mediated event, has been demonstrated [2],
their concomitant activation being essential for ADP-induced
platelet aggregation [3].
These data are in agreement with those of Savi et al. who
demonstrated that the inhibition of platelet aggregation by
A3P5PS, an antagonist of the Gq-coupled ADP receptor
(P2Y1), was restored by the addition of serotonin, a non-
aggregating compound capable of stimulating Gq-coupled
phospholipase C activation [4].
In a previous work we demonstrated that the thromboxane
A2 synthetic agonist, U46619, which causes the selective acti-
vation of Gq without a¡ecting the adenylyl cyclase pathway
[5], was not able to elicit ¢brinogen receptor exposure unless
ADP was present [6]. The same results were obtained in pla-
telets degranulated by means of thrombin and reexposed to
agonists [7,8]. The aim of this study was thus to verify
whether Gi activation is the step U46619 lacks to cause pla-
telet aggregation. For this purpose we studied platelets treated
with an ADP scavenger system subsequently stimulated with
U46619 plus epinephrine, an agonist which is capable of se-
lectively activating the Gi protein and of potentiating platelet
aggregation induced by other agonists which activate Gq
[9,10].
Moreover, since some authors have suggested that among
the events related to the Gq-coupled ADP receptor, cytosolic
calcium increase is a major event for aggregation [11], while
we have demonstrated that the exposure of the platelet ¢bri-
nogen binding site could occur independently of an increase in
cytosolic Ca2 [8], this study was also aimed at delineating the
role of calcium in platelet aggregation in cells treated with the
intracellular calcium chelating agent BAPTA.
2. Materials and methods
Blood samples were collected in acid/citrate/dextrose (ACD) from
informed healthy volunteers who denied having taken any drugs in
the 2 weeks before blood sampling.
Platelet rich plasma (PRP) obtained after centrifugation (180Ug for
15 min) was further centrifuged (800Ug for 20 min) to concentrate the
platelets (6U108 platelets/ml). The concentrated platelets were incu-
bated for 15 min at 37‡C with 1 mM acetylsalicylate (Sigma, St.
Louis, MO, USA) and then gel ¢ltered on Sepharose 2B-CL (Phar-
macia, Uppsala, Sweden) using Ca2-free Tyrode’s bu¡er containing
0.2% albumin (bovine serum fraction V-BSA), 0.1% glucose and
10 mM HEPES (pH 7.35) (all from Sigma).
In some experiments gel ¢ltered platelets (GFP) were treated with
the ADP scavenger system creatine phosphate/creatine kinase (CP/
CPK) (Sigma) before the addition of agonists.
2.1. Preparation of thrombin degranulated platelets (TDP)
The preparation of TDP has been previously described [7]. Brie£y,
before thrombin activation (0.5 U/ml of human K-thrombin, generous
gift of Dr. J.W. Fenton II, NY State Department of Health, Albany,
NY, USA), the GFP were incubated for 5 min at 37‡C with 0.1 mM
Arg-Gly-Asp-Ser (RGDS), 0.12 mM Gly-Pro-Arg-Pro (GPRP),
20 mM creatine phosphate (CP), 50 U/ml creatine kinase (CPK)
and 0.2 mM CaCl2. After 1 min tosyl-arginyl-methyl ester (TAMe)
(10 mM) and hirudin (10 mU/ml) were added as thrombin inhibitors
and ACD (40 Wl/ml of GFP) was used to lower the pH of the sus-
pension to 6.5 (all the products were from Sigma). The platelets were
then washed twice by centrifugation at 800Ug for 10 min and ¢nally
resuspended in Tyrode’s bu¡er.
2.2. Preparation of BAPTA-treated platelets
The concentrated platelets were incubated for 30 min at 37‡C with
1 mM aspirin, 100 WM 1,2-bis(2-aminophenoxy)ethane-N,N,N,N-
tetraacetic acid acetoxymethyl ester (BAPTA-AM) and 3 WM Fura-
2-AM (both from Molecular Probes, Eugene, OR, USA). Excess
BAPTA-AM and Fura-2-AM were separated from the platelets by
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gel ¢ltration. On each preparation changes in intracellular calcium
concentrations in response to thrombin (1 U/ml), U46619 (2 WM)
and ADP (20 WM) were evaluated. The £uorescence changes were
monitored with a Kontron SFM 25 £uorimeter, set at 340 nm exci-
tation and 510 nm emission. Intracellular free calcium was calibrated
according to Grynkiewicz [12]. If the vnM of Ca2 obtained in
response to each agonist was higher than 10 the platelet suspension
was not employed.
2.3. Platelet aggregation
In vitro platelet aggregation was evaluated according to Born [13]
in a four sample PACKS-4 (Helena Laboratories, Beaumont, TX,
USA) aggregometer using siliconized glass cuvettes at 37‡C under
continuous stirring. Fibrinogen (1 mg/ml) (Sigma) was added before
the agonists.
3. Results and discussion
It has recently been demonstrated that ADP-induced plate-
let aggregation is dependent on the coactivation of two di¡er-
ent G protein-coupled receptors, one (P2Y1) coupled to the
activation of Gq and the other (P2TAC) coupled to Gi [3]. The
requirement of converging signalling pathways from the two
di¡erent proteins might explain the inability of the thrombox-
ane A2 agonist U46619 to evoke per se an aggregometric
response in the absence of released ADP [6,8]. To test the
validity of this hypothesis we added epinephrine, which pro-
motes inhibition of adenylyl cyclase by coupling to Gi, to
platelets stimulated with U46619. The results show that the
delayed addition of epinephrine (5 WM), which was not able to
induce platelet aggregation (data not shown), to a suspension
of GFP treated with the ADP scavenger system CP/CPK
(40 mM/100 U/ml) exposed to U46619 (2 WM) resulted in
maximal aggregation (74.0 þ 6.6%), comparable to that ob-
tained in control GFP activated with U46619 (Fig. 1).
Savi et al. [4] have proposed that P2Y1-mediated phospho-
lipase C activation through a Gq-coupled event and the sub-
sequent cytosolic calcium increase might be a major event in
platelet aggregation. In order to investigate the role exerted by
calcium ions in this platelet response we examined a platelet
preparation treated with the intracellular calcium chelating
agent BAPTA in the absence of calcium in the external me-
dium. This platelet suspension was preincubated with minimal
concentrations of CP/CPK (0.4 mM/1 U/ml) since U46619-
induced ADP release was lower than 10% (unpublished
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Fig. 1. Platelet aggregation in response to U46619 (2 WM) plus epinephrine (5 WM) in acetylsalicylate-treated (1 mM) GFP in the presence of
the ADP scavenger system CP/CPK (40 mM/100 U/ml) (B). A: Control, untreated GFP in response to U46619 (2 WM). The ¢gure is represen-
tative of ¢ve experiments performed.
C
Fig. 2. Platelet aggregation patterns in response to ADP (5 WM) (A,
lower curve), U46619 (2 WM) plus ADP (A, upper curve), U46619
(2 WM) plus epinephrine (5 WM) (B) and U46619 (2 WM) plus
SQ22536 (10 WM) (C) in acetylsalicylate-, BAPTA-treated (1 mM
and 100 WM respectively) platelets in the presence of low concentra-
tions of CP/CPK (0.4 mM/1 U/ml). The ¢gure is representative of
¢ve experiments.
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data). Fig. 2 shows that a full aggregation was achievable in
platelets activated with U46619 (2 WM) plus ADP (5 WM) or
epinephrine (5 WM) (87.4 þ 11% and 76.8 þ 14% respectively)
(panels A and B), while the single agonists did not cause any
response (panel A). Since both ADP and epinephrine exert
their action by inhibiting the adenylyl cyclase responsible for
the production of adenosine 3P,5P-cyclic monophosphate
(cAMP), we hypothesized that the reduction of cAMP levels
might be the necessary condition for U46619-induced platelet
aggregation to occur. For this purpose the aggregometric re-
sponse to SQ22536 (10 WM), a drug which inhibits cytosolic
adenylyl cyclase [14], used in combination with U46619 was
evaluated. The results showed that BAPTA-treated GFP did
not respond to this combined stimulation clearly indicating
that the reduction of cAMP concentrations is not the mech-
anism required by U46619 to induce aggregation (Fig. 2C).
O¡ermanns et al. [15] demonstrated that high concentra-
tions (100 WM) of the calcium ionophore A23187 caused a
dramatic secretion followed by aggregation in GKq-de¢cient
mouse platelets, indicating that calcium in£ux is able to acti-
vate a downstream signalling molecule in the two pathways
involving both Gq and Gi. However, this activation seems to
be triggered only by a massive calcium in£ux through the
plasma membrane, since, when we tested the e¡ects of low
concentrations of another calcium ionophore, ionomycin
(0.5 WM), on a suspension of control platelets treated with
CP/CPK (40 mM/100 U/ml), we only observed a reversible
wave of aggregation (16.5 þ 5.3%) (Fig. 3). Nevertheless,
when ionomycin was used synergistically with U46619, it
mimicked the response to epinephrine in potentiating
U46619-induced activation, giving rise to full aggregation
(88.9 þ 7.6%) (Fig. 3). This response was unmodi¢ed if iono-
mycin was added before U46619.
A similar mechanism of ampli¢cation was observed in TDP
in which the ADP stored in the granules had been released; in
fact, platelet aggregation to U46619 was restored by the ad-
dition of ionomycin (0.5 WM) similarly to what we observed
after the addition of ADP (5 WM) (48.6 þ 3.5% and
67.3 þ 4.5% respectively) (Fig. 4).
Conversely, when tested in BAPTA-treated platelets, iono-
mycin, which caused a slight response (23.4 þ 3.7%) when used
at high concentrations (5 WM) in the presence of CaCl2 1mM
(Fig. 5A), was unable to amplify platelet response to U46619
(2 WM) unless calcium was present, the maximum e¡ect being
achieved in the presence of 1 mM CaCl2 (Fig. 5B). The fact
that ionomycin is unable to amplify platelet response to epi-
nephrine, which promotes the inhibition of adenylyl cyclase
by a Gi-coupled mechanism, both in platelets treated with the
ADP scavenger system and in BAPTA-treated platelets (data
not shown), might be explained by assuming that entry of a
small concentration of calcium activates a downstream bio-
chemical pathway coupled to Gi.
Therefore, from our results we can conclude that the coac-
tivation mechanism of two di¡erent subtypes of GTP binding
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Fig. 3. Platelet aggregation patterns in response to U46619 (2 WM)
plus ionomycin (0.5 WM) in acetylsalicylate-treated (1 mM) GFP, in
the presence of CP/CPK (40 mM/100 U/ml). The calcium ionophore
was added either before (upper curve) or after (lower curve)
U46619. The ¢gure is representative of four experiments performed.
Fig. 4. Platelet aggregation patterns in response to U46619 (2 WM)
plus ADP (5 WM) or ionomycin (0.5 WM) in TDP treated with low
concentrations of CP/CPK (0.4 mM/1 U/ml). The ¢gure is represen-
tative of four experiments performed.
Fig. 5. Platelet aggregation patterns in response to ionomycin (5 WM) in the presence of CaCl2 1 mM (A) and to ionomycin (2 WM) plus
U46619 (2 WM) in the absence (a) and in the presence of increasing concentrations of CaCl2 (b: 0.2 mM; c: 0.5 mM; d: 1 mM) in acetylsalicy-
late-, BAPTA-treated (1 mM and 100 WM respectively) platelets. The ¢gure is representative of six experiments performed.
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proteins, Gi and Gq, may be required for U46619-induced
platelet aggregation, and that the activation of these two G
proteins does not require any increase in cytosolic calcium
concentration.
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